<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="158070">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01857193</url>
  </required_header>
  <id_info>
    <org_study_id>CLEE011X2106</org_study_id>
    <nct_id>NCT01857193</nct_id>
  </id_info>
  <brief_title>Phase Ib/II Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of ER+ Her2- Advanced Breast Cancer</brief_title>
  <official_title>A Phase Ib/II Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive, Her2- Locally Advanced or Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Hong Kong: Department of Health</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To estimate the MTD(s) and/ or RP2D of LEE011 in combination with everolimus + exemestane,
      and LEE011 in combination with exemestane, and to characterize the safety and tolerability
      of the combinations of everolimus + exemestane ± LEE011 and LEE011 + exemestane in patients
      with ER+ HER2- advanced breast cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary purpose of the phase Ib part of this study is to determine the maximum tolerated
      dose(s) (MTD(s)) and/or recommended phase II dose (RP2D) of LEE011 + everolimus + exemestane
      in patients with ER+ Her2- advanced breast cancer. This part of the study will also assess
      safety, tolerability, and PK of the LEE011 + exemestane, LEE011 + everolimus + exemestane
      combinations.

      The phase II part of the study will evaluate the triple combination of LEE011 + everolimus +
      exemestane and the double combination of LEE011 + exemestane in comparison to everolimus +
      exemestane. Safety, tolerability and PK (in a subset of patients) will also be assessed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicity (DLT)- Phase Ib</measure>
    <time_frame>Day 1- Day 28 of Cycle 1 (28 day cycle)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>DLT is defined as treatment-related toxicity (classified according Common Toxicity Criteria for Adverse Events (CTCAE) Version 4) occurring during the first 28 treatment days and meeting specific protocol-predefined criteria. The information will be integrated in a Bayesian logistic regression model with overdose control to estimate the maximum tolerated dose (MTD).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)- Phase II</measure>
    <time_frame>Approximately 26 months after FPFV</time_frame>
    <safety_issue>No</safety_issue>
    <description>PFS is defined as the date of randomization to the date of the first radiologically documented disease progression (PD) or death due to any cause per local investigator assessment as per RECIST.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse drug reactions</measure>
    <time_frame>Every cycle (1 cycle = 28 days) until study evlauation completion visit</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence of adverse events (based on CTCAE Version 4) summarized by system organ class and/or preferred term, severity and relation to study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events</measure>
    <time_frame>every cycle (1cycle = 28 days) until study evaluation completion</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>based on CTCAE Version 4- summarized by system organ class and/or preferred term, severity and relation to study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration-time profiles - Phase Ib/II</measure>
    <time_frame>6 cycles of treatment (28-day cycles)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma PK parameters of LEE011 and everolimus and exemestane when given with food and fasted. Phase 1b: Cycle 1/Days 1, 2, 8, 15, 16, 21; Cycles 2, 3, 4, 5, and 6 on Day 1 of each cycle (if applicable). Phase 2: Cycle 1/Days 1 and 15. Cycles 2, 3, 4, 5, and 6 on Day 1 of each cycle (if applicable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)- Phase Ib and Phase II</measure>
    <time_frame>Approximately 26 months after FPFV</time_frame>
    <safety_issue>No</safety_issue>
    <description>ORR is defined as the proportion of patients with a best overall response of complete response or partial response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration Of Response (DOR) - Phase Ib, Phase II</measure>
    <time_frame>Approximately 26 months after FPFV</time_frame>
    <safety_issue>No</safety_issue>
    <description>DOR is calculated as the time from the date of first documented response (complete response (CR) or partial response (PR)) to the first documented date of progression or death due to underlying cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) - Phase II</measure>
    <time_frame>Approximately 26 months after FPFV</time_frame>
    <safety_issue>No</safety_issue>
    <description>OS is defined as the time from date of randomization/start of treatment to date of death due to any cause. If a patient is not known to have died, survival will be censored at the date of last known date patient alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration-time profiles: AUCtau - Phase Ib/II</measure>
    <time_frame>6 Cycles of treatment (28 day cycles)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma PK parameters of LEE011 and everolimus and exemestane when given with food and fasted. Phase 1b: Cycle 1/Days 1, 2, 8, 15, 16, 21; Cycles 2, 3, 4, 5, and 6 on Day 1 of each cycle (if applicable). Phase 2: Cycle 1/Days 1 and 15. Cycles 2, 3, 4, 5, and 6 on Day 1 of each cycle (if applicable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration-time profiles - Cmin Phase Ib/II</measure>
    <time_frame>6 Cycles of treatment (28 day cycles)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma PK parameters of LEE011 and everolimus and exemestane when given with food and fasted. Phase 1b: Cycle 1/Days 1, 2, 8, 15, 16, 21; Cycles 2, 3, 4, 5, and 6 on Day 1 of each cycle (if applicable). Phase 2: Cycle 1/Days 1 and 15. Cycles 2, 3, 4, 5, and 6 on Day 1 of each cycle (if applicable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration-time profiles - Cmax Phase Ib/II</measure>
    <time_frame>6 Cycles of treatment (28 day cycles)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma PK parameters of LEE011 and everolimus and exemestane when given with food and fasted. Phase 1b: Cycle 1/Days 1, 2, 8, 15, 16, 21; Cycles 2, 3, 4, 5, and 6 on Day 1 of each cycle (if applicable). Phase 2: Cycle 1/Days 1 and 15. Cycles 2, 3, 4, 5, and 6 on Day 1 of each cycle (if applicable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration-time profiles - Tmax Phase Ib/II</measure>
    <time_frame>6 Cycles of treatment (28 day cycles)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma PK parameters of LEE011 and everolimus and exemestane when given with food and fasted. Phase 1b: Cycle 1/Days 1, 2, 8, 15, 16, 21; Cycles 2, 3, 4, 5, and 6 on Day 1 of each cycle (if applicable). Phase 2: Cycle 1/Days 1 and 15. Cycles 2, 3, 4, 5, and 6 on Day 1 of each cycle (if applicable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration-time profiles - Racc Phase Ib/II</measure>
    <time_frame>6 Cycles of treatment (28 day cycles)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma PK parameters of LEE011 and everolimus and exemestane when given with food and fasted. Phase 1b: Cycle 1/Days 1, 2, 8, 15, 16, 21; Cycles 2, 3, 4, 5, and 6 on Day 1 of each cycle (if applicable). Phase 2: Cycle 1/Days 1 and 15. Cycles 2, 3, 4, 5, and 6 on Day 1 of each cycle (if applicable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) - Phase Ib, Phase II</measure>
    <time_frame>Approximately 26 months after FPFV</time_frame>
    <safety_issue>No</safety_issue>
    <description>DCR is the proportion of patients with a best overall response of CR or PR or SD.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">185</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>L-R-E arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEE011 + everolimus + exemestane triple combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L-E arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEE011 + exemestane double combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R-E arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>everolimus + exemestane double combination</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEE011</intervention_name>
    <description>LEE011 is taken orally once per day for 21 days of each 28 day cycle. LEE011 comes in 50 mg and 200 mg capsules.</description>
    <arm_group_label>L-R-E arm</arm_group_label>
    <arm_group_label>L-E arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exemestane</intervention_name>
    <description>Exemestane is taken orally once per day. Exemestane comes in 25 mg tablets.</description>
    <arm_group_label>L-R-E arm</arm_group_label>
    <arm_group_label>L-E arm</arm_group_label>
    <arm_group_label>R-E arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Everolimus is taken orally once per day. Everolimus comes in 1 mg, 2.5 mg, 5mg, and 7.5 mg tablets</description>
    <arm_group_label>L-R-E arm</arm_group_label>
    <arm_group_label>R-E arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult women (≥ 18 years of age) with metastatic or locally advanced breast cancer not
             amenable to curative treatment by surgery or radiotherapy

          -  Histological or cytological confirmation of estrogen-receptor positive (ER+) breast
             cancer

          -  A representative tumor specimen must be available for molecular testing.  An archival
             tumor sample may be submitted; if one is not available, a newly obtained tumor
             specimen must be submitted instead

          -  Postmenopausal women. Postmenopausal status is defined either by:

          -  Age ≥ 18 with prior bilateral oophorectomy

          -  Age ≥ 60 years

          -  Age &lt;60 years with amenorrhea for at least 12 months and both follicle-stimulating
             hormone (FSH) and estradiol levels are in postmenopausal range (according to the
             local laboratory)

          -  Recurrence while on, or within 12 months of end of adjuvant treatment with letrozole
             or anastrozole, or

          -  Progression while on, or within one month of end of letrozole or anastrozole
             treatment for locally advanced or metastatic breast cancer.

          -  Patients must have:

               -  Measurable disease*: At least one lesion that can be accurately measured in at
                  least one dimension ≥ 20 mm with conventional imaging techniques or ≥ 10 mm with
                  spiral CT or MRI or

               -  Bone lesions: lytic or mixed (lytic + sclerotic) in the absence of measurable
                  disease as defined above.

          -  ECOG Performance Status 0-1.

          -  Fasting serum cholesterol ≤ 300 mg/dl or 7.75 mmol/L and fasting triglycerides ≤ 2.5
             × ULN. In case one or both of these thresholds are exceeded, the patient can only be
             included after initiation of statin therapy and when the above mentioned values have
             been achieved.

               -  Exception for Phase Ib patients: measurable disease is not required

        Exclusion Criteria:

          -  Her2-overexpressing patients by local laboratory testing (IHC 3+ staining or in situ
             hybridization positive).

          -  Patients who received more than one chemotherapy line for advanced breast cancer.

          -  Previous treatment with CDK4/6 inhibitors, exemestane or mTOR inhibitors*.

          -  History of active or symptomatic brain or other CNS metastases.

          -  Impaired cardiac function or clinically significant cardiac diseases, including any
             of the following:

          -  Left ventricular ejection fraction (LVEF) &lt; 45% or less than the institution lower
             limit of normal as determined by multiple gated acquisition scan (MUGA) or
             echocardiogram (ECHO)

          -  Congenital long QT syndrome or family history of unexpected sudden cardiac death

          -  QT corrected with Fredericia's (QTcF) &gt;470 ms for females on screening ECG

          -  Any other clinically significant heart disease such as angina pectoris, resting
             bradycardia, left bundle branch block, ventricular tachyarrhythmia, unstable atrial
             fibrillation, Right bundle branch block with left anterior hemiblock (bifascicular
             block), acute myocardial infarction or any heart disease that requires the use of a
             cardiac pacemaker or implantable cardioverter defibrillator ≤ 3 months prior to
             starting study drug.

          -  Patients who are currently receiving treatment with agents that are known to cause
             QTc prolongation in humans.

          -  Patients who are currently receiving treatment (within five days prior to
             randomization) with agents that are metabolized predominantly through CYP3A4 and that
             have a narrow therapeutic window.  Agents that are known strong inducers or
             inhibitors CYP3A4 are prohibited (Refer to Appendix 4) * Exceptions for Phase Ib
             patients:

               1. Patients who received more than two prior lines of chemotherapy are eligible

               2. Patients who received CDK4/6 inhibitors, exemestane or mTOR inhibitors are
                  eligible
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone_ext>+41613241111</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Highlands Oncology Group Dept of Highlands Oncology Grp</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amanda Nickel</last_name>
      <phone>+1 479 872 8130</phone>
      <email>anickel@hogonc.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Thaddeus Beck</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Arkansas/ Arkansas Cancer Research Center Dept of Onc</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cindy Witkowski</last_name>
      <phone>501-686-8503</phone>
      <email>clwitkowski@uams.edu</email>
    </contact>
    <investigator>
      <last_name>Laura Hutchins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California at Los Angeles UCLA SC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kim Kelly</last_name>
      <phone>+1 310 582 6324</phone>
      <email>kmkelly@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Sara Alsterlind Hurvitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Premiere Oncology/Pinnacle Oncology Hematology Dept.ofPremiereOncologyAZ</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kristina Will</last_name>
      <phone>480-860-5000</phone>
      <email>kwill@azpoh.com</email>
    </contact>
    <investigator>
      <last_name>Giraldo Kato</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Onc Dept</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthew Diemer</last_name>
      <phone>720-848-0664</phone>
      <email>matthew.diemer@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer Diamond</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Research Institute Dept of Oncology</name>
      <address>
        <city>Davie</city>
        <state>Florida</state>
        <zip>33328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Diane Chambers</last_name>
      <phone>954-582-1850</phone>
      <email>dianec@flcancercare.com</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Tan-Chiu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine/Winship Cancer Institute Emory</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kim Nguyen</last_name>
      <phone>404-778-4824</phone>
      <email>kim.t.nguyen@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Ruth M. O'Regan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Specialists, SC Dept.of Oncology Specialists</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068-0736</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Milenna Undda</last_name>
      <phone>847-410-0660</phone>
      <email>mundda@oncmed.net</email>
    </contact>
    <investigator>
      <last_name>Sigrun Hallmeyer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Horizon Oncology Center Horizon Onc</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Larry Bisiryu</last_name>
      <email>lbisryu@horizonbioadvance.com</email>
    </contact>
    <investigator>
      <last_name>Wael Harb</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Onc Dept</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taylor T Mazac</last_name>
      <phone>617-643-2208</phone>
      <email>tmazac@partners.org</email>
    </contact>
    <investigator>
      <last_name>Aditya Bardia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wayne State University/Karmanos Cancer Institute Dept of Onc</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gail the Newth</last_name>
      <phone>+1 313 576 8096</phone>
      <email>iversb@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Muaiad Kittaneh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center Oncology Dept.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerry O'Neill</last_name>
      <phone>646-888-5341</phone>
      <email>oneiilg@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Shanu N. Modi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center- New York Presbyterian Onc Dept</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mary Ann Kiernan</last_name>
      <phone>212-304-5579</phone>
      <email>mk3007@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Kevin Kalinsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina UNC 2</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chirstine Tomari</last_name>
      <phone>919-966-4432</phone>
      <email>NCOncologyIDS@unch.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Carey K. Anders</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State Comprehensive Cancer Center/James Cancer Hospital Ohio State</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caitlin Spontelli</last_name>
      <phone>614-293-6401</phone>
      <email>caitlin.spontelli@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Bhuvaneswari Ramaswamy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University SC-5</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Hansen</last_name>
      <phone>503-418-9736</phone>
      <email>hansedan@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen Chui</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center Dept of Onc</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8527</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Diadria Thomas</last_name>
      <phone>214-648-5107</phone>
      <email>Diadra.thomas@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Arthur Frankel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas/MD Anderson Cancer Center Onc Dept</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Westerhold</last_name>
      <phone>713-792-2921</phone>
      <email>DIWesterhold@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Marianna Chavez-MacGregor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>East Bentleigh</city>
        <state>Victoria</state>
        <zip>3165</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6005</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Auckland</city>
        <zip>92024</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Herblain cedex</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bergamo</city>
        <state>BG</state>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cona</city>
        <state>FE</state>
        <zip>44100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <zip>35100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Verona</city>
        <state>VR</state>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hospitalet de LLobregat</city>
        <state>Catalunya</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 11, 2014</lastchanged_date>
  <firstreceived_date>May 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Open label; dose escalation; ER+; LEE011; CDK4/6; everolimus; advanced breast cancer; mTor; HR+; Her2-</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Exemestane</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
